Magnus Spangsberg Boesen1, Malene Landbo Børresen2,3, Søren Kirchhoff Christensen4, Amalie Wandel Klein-Petersen2, Sahla El Mahdaoui5, Malini Vendela Sagar6, Emilie Schou6, Anna Korsgaard Eltvedt7, Maria Jose Miranda7, Alfred Peter Born2, Peter Vilhelm Uldall2, Lau Caspar Thygesen8, Melita Cacic Hribljan9. 1. Department of Neurology, Zealand University Hospital, Sygehusvej 10, 4000, Roskilde, Denmark. magnus.spangsberg.boesen@regionh.dk. 2. Department of Paediatrics and Adolescent Medicine, Copenhagen University Hospital, Copenhagen, Denmark. 3. Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark. 4. Department of Neurology, Zealand University Hospital, Sygehusvej 10, 4000, Roskilde, Denmark. 5. Department of Neurology, Danish Multiple Sclerosis Center, Copenhagen University Hospital, Glostrup, Denmark. 6. Department of Neurology, Copenhagen University Hospital, Glostrup, Denmark. 7. Department of Paediatrics, Herlev Hospital, Herlev, Denmark. 8. National Institute of Public Health, University of Southern Denmark, Copenhagen, Denmark. 9. Department of Clinical Neurophysiology, Copenhagen University Hospital, Copenhagen, Denmark.
Abstract
BACKGROUND: We aimed to determine school performance and psychiatric comorbidity in juvenile absence epilepsy (JAE), juvenile myoclonic epilepsy (JME), and generalized tonic-clonic seizures (GTCS) alone. METHODS: All children (< 18 years) fulfilled International League Against Epilepsy criteria after review of their medical records. Control groups were the pediatric background population or children with non-neurological chronic disease. Outcomes were on school performance and psychiatric comorbidity. We compared mean grade point averages using linear regression and estimated hazard ratios using Cox regression in the remaining analyses. We adjusted for the child's sex, age, and year of birth; and parental highest education, receipt of cash benefits or early retirement. RESULTS: We included 92 JAE, 190 JME, 27 GTCS alone, 15,084 non-neurological chronic disease controls, and population controls. JAE had two times increased hazard for special needs education compared with age-matched population controls (hazard ratio 2.2, 95% CI = 1.1‒4.6, p = 0.03); this was not seen in JME. Compared with population controls, both JAE and JME had lower grade point average in secondary and high school (JME: 9th grade: - 0.5 points, 95% CI = -0.9 to -0.06, p = 0.03; high school: - 0.6 points, 95% CI = -1.3 to -0.1, p = 0.04), and 8% fewer JME and 15% fewer JAE attended high school. Both JME and JAE had higher hazard for redeeming sleep medication compared with non-neurological chronic disease; additionally, JAE had increased hazard for ADHD medicine redemptions. CONCLUSIONS: Both JAE and JME had marginally poorer school performance; performance seemed worse in JAE than in JME. Both JAE and JME had increased use of sleep medication.
BACKGROUND: We aimed to determine school performance and psychiatric comorbidity in juvenile absence epilepsy (JAE), juvenile myoclonic epilepsy (JME), and generalized tonic-clonic seizures (GTCS) alone. METHODS: All children (< 18 years) fulfilled International League Against Epilepsy criteria after review of their medical records. Control groups were the pediatric background population or children with non-neurological chronic disease. Outcomes were on school performance and psychiatric comorbidity. We compared mean grade point averages using linear regression and estimated hazard ratios using Cox regression in the remaining analyses. We adjusted for the child's sex, age, and year of birth; and parental highest education, receipt of cash benefits or early retirement. RESULTS: We included 92 JAE, 190 JME, 27 GTCS alone, 15,084 non-neurological chronic disease controls, and population controls. JAE had two times increased hazard for special needs education compared with age-matched population controls (hazard ratio 2.2, 95% CI = 1.1‒4.6, p = 0.03); this was not seen in JME. Compared with population controls, both JAE and JME had lower grade point average in secondary and high school (JME: 9th grade: - 0.5 points, 95% CI = -0.9 to -0.06, p = 0.03; high school: - 0.6 points, 95% CI = -1.3 to -0.1, p = 0.04), and 8% fewer JME and 15% fewer JAE attended high school. Both JME and JAE had higher hazard for redeeming sleep medication compared with non-neurological chronic disease; additionally, JAE had increased hazard for ADHD medicine redemptions. CONCLUSIONS: Both JAE and JME had marginally poorer school performance; performance seemed worse in JAE than in JME. Both JAE and JME had increased use of sleep medication.
Authors: Jette Kolding Kristensen; Thomas B Drivsholm; Bendix Carstensen; Marianne Steding-Jensen; Anders Green Journal: Ugeskr Laeger Date: 2007-04-30
Authors: Peter Uggerby; Søren Dinesen Østergaard; Rasmus Røge; Christoph U Correll; Jimmi Nielsen Journal: Dan Med J Date: 2013-02 Impact factor: 1.240